- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-3 trial, a phase III trial for patients with metastatic hormone-sensitive prostate cancer with DNA repair gene-related alterations or homologous recombination repair gene alterations in the tumors. The trial is ongoing, and accrual is expected to be completed soon. Ultimately, the trial aims to comprehensively assess efficacy, safety, and...
|
- Details
- Alicia Morgans engages with Fred Saad to discuss a network meta-analysis concerning treatments for patients with metastatic hormone-sensitive prostate cancer. They explore the controversies surrounding the most effective treatment for newly diagnosed disease, considering factors like disease volume and whether it's recurrent or de novo. Dr. Saad explains the diminishing role of ADT alone, emphasiz...
|
- Details
- In this discussion, Christopher Wallis discusses treatment intensification in metastatic castrate-sensitive prostate cancer (mCSPC). Dr. Klaassen and Dr. Wallis focus their discussion on several studies in the United States and across the globe that have looked at the real-world utilization of androgen deprivation therapy (ADT) plus other agents in the mCSPC disease space. Drs. Klaassen and Wallis...
|
- Details
- Alicia Morgans is joined in conversation by Evan Yu to discuss the integration of triplet therapy into clinical practice for metastatic prostate cancer patients focusing on the patient population for this therapy. The conversation also includes discussing chemo-fit patients and the presentation of chemotherapy and triplet therapy as a standard for patients to refuse, emphasizing the need for activ...
|
- Details
- Alicia Morgans interviews Ben Maughan focusing on a published network meta-analysis involving 11 randomized control trials for patients treated for metastatic hormone-sensitive prostate cancer. The analysis stirred significant debate on Twitter and sought to establish whether triplet therapy was superior to other approaches like ADT plus docetaxel and ADT plus an AR-targeted therapy. Dr. Maughan e...
|
- Details
- In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....
|
- Details
- Karim Fizazi discusses the substantial progress made in treating metastatic castration-sensitive prostate cancer. In their conversation, Dr. Fizazi emphasizes the importance of understanding different patient scenarios based on volume and the timing of the metastasis, highlighting the distinctions between de novo metastatic disease and relapse after local treatment. He breaks down four scenarios t...
|
- Details
- At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022: Treatment...
|
- Details
- Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...
|